title: Overseeing research on therapeutic cloning: a private ethics board responds to its critics.
abstract: Advanced Cell Technology's Ethics Advisory Board has been called window dressing for a corporate marketing plan. But the scientists and managers have paid attention, and the lawyers have gone along.
authors.forename: Ronald M
authors.initials: RM
authors.lastname: Green
authors.forename: Kier Olsen
authors.initials: KO
authors.lastname: DeVries
authors.forename: Judith
authors.initials: J
authors.lastname: Bernstein
authors.forename: Kenneth W
authors.initials: KW
authors.lastname: Goodman
authors.forename: Robert
authors.initials: R
authors.lastname: Kaufmann
authors.forename: Ann A
authors.initials: AA
authors.lastname: Kiessling
authors.forename: Susan R
authors.initials: SR
authors.lastname: Levin
authors.forename: Susan L
authors.initials: SL
authors.lastname: Moss
authors.forename: Carol A
authors.initials: CA
authors.lastname: Tauer
mesh_terms: D001675:Bioethics; D035843:Biomedical Research; D019976:Cloning, Organism / Q000941:ethics*; D016265:Conflict of Interest; D030881:Disclosure; D028744:Ethics Committees, Research / Q000592:standards*; D005378:Financial Support; D006801:Humans; D009014:Morals; D017149:Private Sector / Q000592:standards*; D035842:Research Subjects